Tirzepatide in Jacksonville
What Is Tirzepatide?
Tirzepatide is a type 2 diabetes medication that not only manages blood sugar levels but also aids weight loss in eligible patients. This drug, which is the active ingredient in Mounjaro, functions by mimicking the effects of two hormones that regulate blood sugar: Glucagon-like peptide-1 (GLP-1) and Glucose-dependent insulinotropic polypeptide (GIP). GIP also reduces appetite, while Tirzepatide additionally influences food intake and energy expenditure to promote weight reduction.
Our resident weight loss physician, Dr. Blissenbach, can prescribe Tirzepatide injections for individuals residing in our Jacksonville service area. To see if you qualify for our weight loss injections, schedule an appointment below.
Schedule a FREE consultation by filling out the form below!
Tirzepatide (the active ingredient in Mounjaro) is a new medication that is being developed for the treatment of obesity and type 2 diabetes. It is a once-weekly injection that works by activating three hormones in the body that regulate blood sugar and appetite: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP), and glucagon.
The activation of these hormones leads to several benefits that can aid in weight loss, including reduced appetite, increased feelings of fullness, and decreased food intake. In clinical trials, tirzepatide has shown promising results in helping people lose weight and manage their blood sugar levels.
One study published in the New England Journal of Medicine found that tirzepatide led to an average weight loss of around 15% in participants with obesity, compared to around 2% for those who received a placebo. The medication was also effective in improving blood sugar control and reducing the risk of cardiovascular events.
In summary, tirzepatide is a new medication that is being developed for the treatment of obesity and type 2 diabetes. It works by activating hormones that regulate blood sugar and appetite, leading to weight loss and improved blood sugar control. However, it should only be used under the supervision of a healthcare professional.
More reading: Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022 Jul 21;387(3):205-216. doi: 10.1056/NEJMoa2206038. Epub 2022 Jun 4. PMID: 35658024.